Dry Eye Clinical Trial
Official title:
Evaluation of Ocular Surface in Hemodialysis Patients by Ocular Surface Analyzer
NCT number | NCT04949295 |
Other study ID # | 2021JN |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | January 1, 2021 |
Est. completion date | December 31, 2021 |
Verified date | April 2022 |
Source | First Affiliated Hospital of Jinan University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
We clinically observed that some hemodialysis patients had corneal epithelial dryness, shedding, edema, and persistent epithelial nonunion after ocular surgery, which seriously affected the effect of surgery, and it is necessary to study the ocular surface characteristics of hemodialysis patients. In this study, we examined the ocular surface and analyzed and investigated the characteristics of the ocular surface in hemodialysis patients to provide a basis for ocular surface intervention or treatment in hemodialysis patients before ocular surgery in clinical practice.
Status | Completed |
Enrollment | 36 |
Est. completion date | December 31, 2021 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 25 Years to 72 Years |
Eligibility | the hemodialysis group Inclusion Criteria: - Older than 18 - Hemodialysis patient - The subject understands the purpose of this clinical trial and agrees to sign an informed consent form. the hemodialysis group Exclusion Criteria: - Previous history of ocular trauma or surgery - History of wearing contact lenses - Can Not Stop the use of dry eye caused by drugs and other drugs may directly affect the stability of tear film tears - Eyelid abnormalities (such as eyelid insufficiency, entropion and ECTROPION, tumor, severe trichiasis) - There have been peritoneal dialysis, kidney transplant surgery patients. the normal group Inclusion Criteria: - Older than 18 - Healthy people do not have other systemic diseases, such as diabetes and hypertension - The subject understands the purpose of this clinical trial and agrees to sign an informed consent form. the normal group Exclusion Criteria: - Previous history of ocular trauma or surgery - History of wearing contact lenses - Can Not Stop the use of dry eye caused by drugs and other drugs may directly affect the stability of tear film tears. |
Country | Name | City | State |
---|---|---|---|
China | The First Affiliated Hospital of Jinan University | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
XiaoYong Liu |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Non-invasive tear meniscus height | Maximum and minimum of Non-invasive tear meniscus height in millimetre,higher scores mean a better outcome. | 1year | |
Primary | first tear film break-up time | Maximum and minimum of first tear film break-up time in Seconds,higher scores mean a better outcome. | 1year | |
Primary | average tear film break-up time | Maximum and minimum of average tear film break-up time in Seconds,higher scores mean a better outcome. | 1year | |
Primary | dry eye severity grade | Maximum and minimum of dry eye severity grade,higher scores mean a worse outcome. | 1year | |
Primary | tear film lipid layer analysis (distribution and color) | Maximum and minimum of tear film lipid layer analysis (distribution and color),higher scores mean a better outcome. | 1year | |
Primary | tear film lipid layer thickness grade | Maximum and minimum of tear film lipid layer thickness grade,higher scores mean a better outcome. | 1year | |
Primary | meibomian gland opening blocking site | Maximum and minimum of meibomian gland opening blocking site,higher scores mean a worse outcome. | 1year | |
Primary | meibomian gland opening blocking analysis | Maximum and minimum of meibomian gland opening blocking analysis,higher scores mean a worse outcome. | 1year | |
Primary | meibomian gland opening secretion oil character score | Maximum and minimum of meibomian gland opening secretion oil character score,higher scores mean a worse outcome. | 1year | |
Primary | eye redness index analysis (conjunctiva, ciliary shape) | Maximum and minimum of eye redness index analysis (conjunctiva, ciliary shape),higher scores mean a worse outcome. | 1year | |
Primary | meibomian gland absence area score | Maximum and minimum of meibomian gland absence area score,higher scores mean a worse outcome. | 1year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06159569 -
Performance and Tolerability of the Medical Device LACRIACT
|
N/A | |
Completed |
NCT05027087 -
The Effect of a Novel Blueberry Supplement on Dry Eye Disease
|
Phase 3 | |
Completed |
NCT05102409 -
An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease
|
Phase 2 | |
Completed |
NCT04081610 -
Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution
|
Phase 1 | |
Completed |
NCT05062564 -
Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye
|
N/A | |
Completed |
NCT05825599 -
PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms
|
N/A | |
Completed |
NCT03418727 -
Dry Eye Disease Study With Brimonidine
|
Phase 2 | |
Active, not recruiting |
NCT04425551 -
Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction
|
N/A | |
Recruiting |
NCT04527887 -
Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)
|
Phase 4 | |
Not yet recruiting |
NCT06379685 -
Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.
|
Phase 1 | |
Active, not recruiting |
NCT05618730 -
Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B
|
Phase 1 | |
Completed |
NCT04553432 -
Dry Eye OmniLenz Application of Omnigen Research Study
|
Phase 4 | |
Recruiting |
NCT04109170 -
Dry Eye Evaluation System Based on Bioinformatics
|
||
Completed |
NCT04105842 -
Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type
|
N/A | |
Completed |
NCT05505292 -
Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
|
Phase 4 | |
Completed |
NCT04668131 -
Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease
|
N/A | |
Completed |
NCT06176651 -
Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers
|
Phase 4 | |
Not yet recruiting |
NCT02218827 -
Topical Steroid Treatment For Dry Eye
|
N/A | |
Completed |
NCT02235259 -
Efficacy and Safety of XG-104 for the Treatment of Dry Eye
|
Phase 2 | |
Completed |
NCT01959854 -
Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye
|
N/A |